The next generation recombinant human cytomegalovirus vaccine candidates-Beyond gB

Vaccine

Volumn 30, Issue 49, 2012, Pages 6980-6990

  Lilja, Anders E ^a   Mason, Peter W ^a  

^a Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Antigen; Cytomegalovirus; Neutralizing antibodies; T cells; Vaccine

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; EPITOPE; MIFAMURTIDE; PEPTIDE VACCINE; POLOXAMER; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS FUSION PROTEIN;

ADJUVANT THERAPY; ALPHA VIRUS; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FLOW CYTOMETRY; GRAFT RECIPIENT; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMORAL IMMUNITY; INJECTION PAIN; MYALGIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPLICON; REVIEW; SINGLE DRUG DOSE; SOCIAL STATUS;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS; ANTIBODIES, VIRAL; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DRUG TOXICITY; GENETIC VECTORS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOLOGIC MEMORY; LYMPHOCYTES; PHOSPHOPROTEINS; RECOMBINANT PROTEINS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84869004878     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.056     Document Type: Review

References (190)

1. Powers C., DeFilippis V., Malouli D., Fruh K. Cytomegalovirus immune evasion. Curr Top Microbiol Immunol 2008, 325:333-359.
2. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields virology 2007, 2699-2772. Lippincott Williams & Wilkins. D.M. Knipe, P.M. Howley (Eds.).
3. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010, 20(July (4)):202-213.
4. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008, 325:417-470.
5. Simanek A.M., Dowd J.B., Pawelec G., Melzer D., Dutta A., Aiello A.E. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS ONE 2011, 6(2):e16103.
6. Steininger C., Puchhammer-Stockl E., Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol 2006, 37(September (1)):1-9.
7. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008, 8(October (5)):541-548.
8. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113(June (23)):5711-5719.
9. Bonaros N., Mayer B., Schachner T., Laufer G., Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008, 22(January-February (1)):89-97.
10. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353(September (13)):1350-1362.
11. Nigro G., Adler S.P., Parruti G., Anceschi M.M., Coclite E., Pezone I., et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children. J Infect Dis 2012, 205(January (2)):215-227.
12. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39(July (2)):233-239.
13. Cannon M.J., Hyde T.B., Schmid D.S. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol 2011, 21(July (4)):240-255.
14. Sinzger C., Digel M., Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 2008, 325:63-83.
15. Reeves M., Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 2008, 325:297-313.
16. Bale J.F., Petheram S.J., Souza I.E., Murph J.R. Cytomegalovirus reinfection in young children. J Pediatr 1996, 128(March (3)):347-352.
17. Boppana S.B., Rivera L.B., Fowler K.B., Mach M., Britt W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001, 344(May (18)):1366-1371.
18. Chou S.W. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986, 314(May (22)):1418-1423.
19. Ross S.A., Arora N., Novak Z., Fowler K.B., Britt W.J., Boppana S.B. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010, 201(February (3)):386-389.
20. Yamamoto A.Y., Mussi-Pinhata M.M., Boppana S.B., Novak Z., Wagatsuma V.M., Oliveira Pde F., et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 2009, 202(March (3)):297.e1-297.e8.
21. Fowler K.B., Stagno S., Pass R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003, 289(February (8)):1008-1011.
22. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992, 326(March (10)):663-667.
23. Boppana S.B., Britt W.J. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995, 171(May (5)):1115-1121.
24. Ahlfors K., Ivarsson S.A., Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 1999, 31(5):443-457.
25. Boppana S.B., Fowler K.B., Britt W.J., Stagno S., Pass R.F. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999, 104(July (1 Pt 1)):55-60.
26. Gallant J.E., Moore R.D., Richman D.D., Keruly J., Chaisson R.E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992, 166(December (6)):1223-1227.
27. Gerard L., Leport C., Flandre P., Houhou N., Salmon-Ceron D., Pepin J.M., et al. Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997, 24(May (5)):836-840.
28. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992, 5(11):1069-1074.
29. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338(Jun (24)):1741-1751.
30. Quinnan G.V., Kirmani N., Rook A.H., Manischewitz J.F., Jackson L., Moreschi G., et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982, 307(July (1)):7-13.
31. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257(July (5067)):238-241.
32. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333(October (16)):1038-1044.
33. Krmpotic A., Bubic I., Polic B., Lucin P., Jonjic S. Pathogenesis of murine cytomegalovirus infection. Microbes Infect 2003, 5(November (13)):1263-1277.
34. Rawlinson W.D., Farrell H.E., Barrell B.G. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 1996, 70(December (12)):8833-8849.
35. Schleiss M.R. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol 2002, 25(August (Suppl. 2)):S37-S49.
36. Yue Y., Barry P.A. Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res 2008, 72:207-226.
37. Gibson W. Structure and formation of the cytomegalovirus virion. Curr Top Microbiol Immunol 2008, 325:187-204.
38. Murphy E., Yu D., Grimwood J., Schmutz J., Dickson M., Jarvis M.A., et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA 2003, 100(December (25)):14976-14981.
39. Varnum S.M., Streblow D.N., Monroe M.E., Smith P., Auberry K.J., Pasa-Tolic L., et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 2004, 78(October (20)):10960-10966.
40. Ryckman B.J., Chase M.C., Johnson D.C. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci USA 2008, 105(September (37)):14118-14123.
41. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005, 102(December (50)):18153-18158.
42. Stanton R.J., Baluchova K., Dargan D.J., Cunningham C., Sheehy O., Seirafian S., et al. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 2010, 120(September (9)):3191-3208.
43. Rigoutsos I., Novotny J., Huynh T., Chin-Bow S.T., Parida L., Platt D., et al. In silico pattern-based analysis of the human cytomegalovirus genome. J Virol 2003, 77(April (7)):4326-4344.
44. Chen D.H., Jiang H., Lee M., Liu F., Zhou Z.H. Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus. Virology 1999, 260(July (1)):10-16.
45. Yu X., Shah S., Lee M., Dai W., Lo P., Britt W., et al. Biochemical and structural characterization of the capsid-bound tegument proteins of human cytomegalovirus. J Struct Biol 2011, 174(June (3)):451-460.
46. Baldick C.J., Shenk T. Proteins associated with purified human cytomegalovirus particles. J Virol 1996, 70(September (9)):6097-6105.
47. Terhune S.S., Schroer J., Shenk T. RNAs are packaged into human cytomegalovirus virions in proportion to their intracellular concentration. J Virol 2004, 78(October (19)):10390-10398.
48. Kalejta R.F. Functions of human cytomegalovirus tegument proteins prior to immediate early gene expression. Curr Top Microbiol Immunol 2008, 325:101-115.
49. Vanarsdall A.L., Johnson D.C. Human cytomegalovirus entry into cells. Curr Opin Virol 2012, 2(February (1)):37-42.
50. Kari B., Gehrz R. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J Virol 1992, 66(March (3)):1761-1764.
51. Kari B., Gehrz R. Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II. J Gen Virol 1993, 74(February (Pt 2)):255-264.
52. Kari B., Li W., Cooper J., Goertz R., Radeke B. The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies. J Gen Virol 1994, 75(November (Pt 11)):3081-3086.
53. Mach M., Kropff B., Dal Monte P., Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 2000, 74(December (24)):11881-11892.
54. Mach M., Kropff B., Kryzaniak M., Britt W. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 2005, 79(February (4)):2160-2170.
55. Hobom U., Brune W., Messerle M., Hahn G., Koszinowski U.H. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 2000, 74(September (17)):7720-7729.
56. Krzyzaniak M., Mach M., Britt W.J. The cytoplasmic tail of glycoprotein M (gpUL100) expresses trafficking signals required for human cytomegalovirus assembly and replication. J Virol 2007, 81(October (19)):10316-10328.
57. Shimamura M., Mach M., Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 2006, 80(May (9)):4591-4600.
58. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010, 84(January (2)):1005-1013.
59. Heldwein E.E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 2008, 65(June (11)):1653-1668.
60. Heldwein E.E., Lou H., Bender F.C., Cohen G.H., Eisenberg R.J., Harrison S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006, 313(July (5784)):217-220.
61. Britt W.J., Vugler L.G. Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). J Virol 1992, 66(November (11)):6747-6754.
62. Carlson C., Britt W.J., Compton T. Expression, purification, and characterization of a soluble form of human cytomegalovirus glycoprotein B. Virology 1997, 239(December (1)):198-205.
63. Backovic M., Longnecker R., Jardetzky T.S. Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci USA 2009, 106(February (8)):2880-2885.
64. Spaete R.R., Thayer R.M., Probert W.S., Masiarz F.R., Chamberlain S.H., Rasmussen L., et al. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988, 167(November (1)):207-225.
65. Vey M., Schafer W., Reis B., Ohuchi R., Britt W., Garten W., et al. Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin. Virology 1995, 206(January (1)):746-749.
66. Britt W.J., Auger D. Synthesis and processing of the envelope gp 55-116 complex of human cytomegalovirus. J Virol 1986, 58(April (1)):185-191.
67. Britt W.J., Vugler L.G. Processing of the gp 55-116 envelope glycoprotein complex (gB) of human cytomegalovirus. J Virol 1989, 63(January (1)):403-410.
68. Strive T., Borst E., Messerle M., Radsak K. Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture. J Virol 2002, 76(February (3)):1252-1264.
69. Reschke M., Reis B., Noding K., Rohsiepe D., Richter A., Mockenhaupt T., et al. Constitutive expression of human cytomegalovirus glycoprotein B (gpUL55) with mutagenized carboxy-terminal hydrophobic domains. J Gen Virol 1995, 76(January (Pt 1)):113-122.
70. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990, 64(March (3)):1079-1085.
71. Potzsch S., Spindler N., Wiegers A.K., Fisch T., Rucker P., Sticht H., et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011, 7(August (8)):e1002172.
72. Marshall G.S., Rabalais G.P., Stout G.G., Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 1992, 165(February (2)):381-384.
73. Meyer H., Masuho Y., Mach M. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 1990, 71(October (Pt 10)):2443-2450.
74. Utz U., Britt W., Vugler L., Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 1989, 63(May (5)):1995-2001.
75. Meyer H., Sundqvist V.A., Pereira L., Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 1992, 73(September (Pt 9)):2375-2383.
76. Ohlin M., Sundqvist V.A., Mach M., Wahren B., Borrebaeck C.A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 1993, 67(February (2)):703-710.
77. Kniess N., Mach M., Fay J., Britt W.J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol 1991, 65(January (1)):138-146.
78. Speckner A., Glykofrydes D., Ohlin M., Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 1999, 80(August (Pt 8)):2183-2191.
79. Axelsson F., Adler S.P., Lamarre A., Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine 2007, 26(December (1)):41-46.
80. Cranage M.P., Smith G.L., Bell S.E., Hart H., Brown C., Bankier A.T., et al. Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H. J Virol 1988, 62(April (4)):1416-1422.
81. Kaye J.F., Gompels U.A., Minson A.C. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product. J Gen Virol 1992, 73(October (Pt 10)):2693-2698.
82. Kinzler E.R., Compton T. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 2005, 79(June (12)):7827-7837.
83. Chowdary T.K., Cairns T.M., Atanasiu D., Cohen G.H., Eisenberg R.J., Heldwein E.E. Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 2010, 17(July (7)):882-888.
84. Matsuura H., Kirschner A.N., Longnecker R., Jardetzky T.S. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Proc Natl Acad Sci USA 2010, 107(December (52)):22641-22646.
85. Atanasiu D., Saw W.T., Cohen G.H., Eisenberg R.J. Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol 2010, 84(December (23)):12292-12299.
86. Plate A.E., Reimer J.J., Jardetzky T.S., Longnecker R. Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL. Virology 2011, 413(April (1)):26-38.
87. Vanarsdall A.L., Ryckman B.J., Chase M.C., Johnson D.C. Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J Virol 2008, 82(December (23)):11837-11850.
88. Vanarsdall A.L., Chase M.C., Johnson D.C. Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol 2011, 85(November (22)):11638-11645.
89. Rasmussen L., Matkin C., Spaete R., Pachl C., Merigan T.C. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991, 164(November (5)):835-842.
90. Urban M., Klein M., Britt W.J., Hassfurther E., Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996, 77(July (Pt 7)):1537-1547.
91. Fouts A.E., Chan P., Stephan J.P., Vandlen R., Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-CMV neutralizing antibody response in CMV-HIG. J Virol 2012, 86(April (13)):7444-7447.
92. Patrone M., Secchi M., Bonaparte E., Milanesi G., Gallina A. Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 2007, 81(October (20)):11479-11488.
93. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008, 82(January (1)):60-70.
94. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78(September (18)):10023-10033.
95. Straschewski S., Patrone M., Walther P., Gallina A., Mertens T., Frascaroli G. Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol 2011, 85(May (10)):5150-5158.
96. Gerna G., Percivalle E., Lilleri D., Lozza L., Fornara C., Hahn G., et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005, 86(February (Pt 2)):275-284.
97. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79(August (16)):10330-10338.
98. Akter P., Cunningham C., McSharry B.P., Dolan A., Addison C., Dargan D.J., et al. Two novel spliced genes in human cytomegalovirus. J Gen Virol 2003, 84(May (Pt 5)):1117-1122.
99. Huber M.T., Compton T. Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex. J Virol 1997, 71(July (7)):5391-5398.
100. Huber M.T., Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 1998, 72(October (10)):8191-8197.
101. Huber M.T., Compton T. Intracellular formation and processing of the heterotrimeric gH-gL-gO (gCIII) glycoprotein envelope complex of human cytomegalovirus. J Virol 1999, 73(May (5)):3886-3892.
102. Li L., Nelson J.A., Britt W.J. Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol 1997, 71(April (4)):3090-3097.
103. Theiler R.N., Compton T. Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells. J Virol 2002, 76(March (6)):2890-2898.
104. Ryckman B.J., Chase M.C., Johnson D.C. Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 2010, 84(March (5)):2597-2609.
105. Wille P.T., Knoche A.J., Nelson J.A., Jarvis M.A., Johnson D.C. A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 2010, 84(March (5)):2585-2596.
106. Jiang X.J., Adler B., Sampaio K.L., Digel M., Jahn G., Ettischer N., et al. UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J Virol 2008, 82(March (6)):2802-2812.
107. Sanchez V., Greis K.D., Sztul E., Britt W.J. Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol 2000, 74(January (2)):975-986.
108. Britt W.J., Auger D. Human cytomegalovirus virion-associated protein with kinase activity. J Virol 1986, 59(July (1)):185-188.
109. Michelson S., Tardy-Panit M., Barzu O. Properties of a human cytomegalovirus-induced protein kinase. Virology 1984, 134(April (2)):259-268.
110. Michelson S., Tardy-Panit M., Barzu O. Catalytic properties of a human cytomegalovirus-induced protein kinase. Eur J Biochem 1985, 149(June (2)):393-399.
111. Somogyi T., Michelson S., Masse M.J. Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68). Virology 1990, 174(January (1)):276-285.
112. Schmolke S., Kern H.F., Drescher P., Jahn G., Plachter B. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 1995, 69(October (10)):5959-5968.
113. Cristea I.M., Moorman N.J., Terhune S.S., Cuevas C.D., O'Keefe E.S., Rout M.P., et al. Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein. J Virol 2010, 84(August (15)):7803-7814.
114. Chevillotte M., Landwehr S., Linta L., Frascaroli G., Luske A., Buser C., et al. Major tegument protein pp65 of human cytomegalovirus is required for the incorporation of pUL69 and pUL97 into the virus particle and for viral growth in macrophages. J Virol 2009, 83(March (6)):2480-2490.
115. Schmolke S., Drescher P., Jahn G., Plachter B. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 1995, 69(February (2)):1071-1078.
116. Abate D.A., Watanabe S., Mocarski E.S. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol 2004, 78(October (20)):10995-11006.
117. Browne E.P., Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA 2003, 100(September (20)):11439-11444.
118. Arnon T.I., Achdout H., Levi O., Markel G., Saleh N., Katz G., et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005, 6(May (5)):515-523.
119. Odeberg J., Plachter B., Branden L., Soderberg-Naucler C. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood 2003, 101(June (12)):4870-4877.
120. Gilbert M.J., Riddell S.R., Plachter B., Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996, 383(October (6602)):720-722.
121. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(September (5)):673-685.
122. Gibson L., Piccinini G., Lilleri D., Revello M.G., Wang Z., Markel S., et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004, 172(February (4)):2256-2264.
123. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002, 185(June (12)):1709-1716.
124. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994, 43(May (1)):103-110.
125. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996, 70(November (11)):7569-7579.
126. Peggs K.S., Thomson K., Samuel E., Dyer G., Armoogum J., Chakraverty R., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52(January (1)):49-57.
127. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99(June (11)):3916-3922.
128. Micklethwaite K.P., Clancy L., Sandher U., Hansen A.M., Blyth E., Antonenas V., et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008, 112(November (10)):3974-3981.
129. Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116(November (20)):4360-4367.
130. Kern F., Surel I.P., Faulhaber N., Frommel C., Schneider-Mergener J., Schonemann C., et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999, 73(October (10)):8179-8184.
131. Khan N., Cobbold M., Keenan R., Moss P.A. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002, 185(April (8)):1025-1034.
132. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000, 181(May (5)):1537-1546.
133. Borysiewicz L.K., Hickling J.K., Graham S., Sinclair J., Cranage M.P., Smith G.L., et al. Human cytomegalovirus-specific cytotoxic T cells, Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988, 168(September (3)):919-931.
134. Meier J.L., Stinski M.F. Major immediate-early enhancer and its gene products. Cytomegaloviruses: molecular biology and immunology 2006, 151-166. Caister Academic Press. M.J. Reddehase (Ed.).
135. Cherrington J.M., Mocarski E.S. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol 1989, 63(March (3)):1435-1440.
136. Stenberg R.M., Fortney J., Barlow S.W., Magrane B.P., Nelson J.A., Ghazal P. Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol 1990, 64(April (4)):1556-1565.
137. Nevels M., Paulus C., Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc Natl Acad Sci USA 2004, 101(December (49)):17234-17239.
138. Huh Y.H., Kim Y.E., Kim E.T., Park J.J., Song M.J., Zhu H., et al. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J Virol 2008, 82(November (21)):10444-10454.
139. Krauss S., Kaps J., Czech N., Paulus C., Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J Virol 2009, 83(December (24)):12854-12870.
140. Paulus C., Krauss S., Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc Natl Acad Sci USA 2006, 103(March (10)):3840-3845.
141. Knoblach T., Grandel B., Seiler J., Nevels M., Paulus C. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. PLoS Pathog 2011, 7(April (4)):e1002016.
142. Wilkinson G.W., Kelly C., Sinclair J.H., Rickards C. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J Gen Virol 1998, 79(May (Pt 5)):1233-1245.
143. Korioth F., Maul G.G., Plachter B., Stamminger T., Frey J. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp Cell Res 1996, 229(November (1)):155-158.
144. Ahn J.H., Brignole E.J., Hayward G.S. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol Cell Biol 1998, 18(August (8)):4899-4913.
145. Maul G.G. Initiation of cytomegalovirus infection at ND10. Curr Top Microbiol Immunol 2008, 325:117-132.
146. Elek S.D., Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974, 1(January (7845)):1-5.
147. Plotkin S.A., Furukawa T., Zygraich N., Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect Immun 1975, 12(September (3)):521-527.
148. Schleiss M.R., Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005, 4(June (3)):381-406.
149. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell D.A., Shope T.C., et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994, 58(December (11)):1176-1178.
150. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991, 114(April (7)):525-531.
151. Balfour H.H., Sachs G.W., Welo P., Gehrz R.C., Simmons R.L., Najarian J.S. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial. Birth Defects Orig Artic Ser 1984, 20(1):289-304.
152. Plotkin S.A., Smiley M.L., Friedman H.M., Starr S.E., Fleisher G.R., Wlodaver C., et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984, 1(March (8376)):528-530.
153. Heineman T.C., Schleiss M., Bernstein D.I., Spaete R.R., Yan L., Duke G., et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006, 193(May (10)):1350-1360.
154. Jacobson M.A., Sinclair E., Bredt B., Agrillo L., Black D., Epling C.L., et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006, 24(June (25)):5311-5319.
155. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001, 183(April (8)):1171-1179.
156. Gonczol E., Berensci K., Pincus S., Endresz V., Meric C., Paoletti E., et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995, 13(August (12)):1080-1085.
157. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999, 180(September (3)):843-846.
158. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999, 180(October (4)):970-975.
159. Norais N., Hall J.A., Gross L., Tang D., Kaur S., Chamberlain S.H., et al. Evidence for a phosphorylation site in cytomegalovirus glycoprotein gB. J Virol 1996, 70(August (8)):5716-5719.
160. Frey S.E., Harrison C., Pass R.F., Yang E., Boken D., Sekulovich R.E., et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999, 180(November (5)):1700-1703.
161. Mitchell D.K., Holmes S.J., Burke R.L., Duliege A.M., Adler S.P. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002, 21(February (2)):133-138.
162. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360(March (12)):1191-1199.
163. Pass R.F., Little E.A., Stagno S., Britt W.J., Alford C.A. Young children as a probable source of maternal and congenital cytomegalovirus infection. N Engl J Med 1987, 316(May (22)):1366-1370.
164. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377(April (9773)):1256-1263.
165. Sabbaj S., Pass R.F., Goepfert P.A., Pichon S., Glycoprotein B. vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011, 203(June (11)):1534-1541.
166. Bernstein D.I., Schleiss M.R., Berencsi K., Gonczol E., Dickey M., Khoury P., et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002, 185(March (5)):686-690.
167. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005, 1(January-February (1)):16-23.
168. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197(June (12)):1634-1642.
169. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12(January (4)):290-9.
170. Jacobson M.A., Adler S.P., Sinclair E., Black D., Smith A., Chu A., et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 2009, 27(March (10)):1540-1548.
171. Reap E.A., Dryga S.A., Morris J., Rivers B., Norberg P.K., Olmsted R.A., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 2007, 14(June (6)):748-755.
172. Reap E.A., Morris J., Dryga S.A., Maughan M., Talarico T., Esch R.E., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007, 25(October (42)):7441-7449.
173. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(December (2)):484-493.
174. La Rosa C., Wang Z., Brewer J.C., Lacey S.F., Villacres M.C., Sharan R., et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002, 100(November (10)):3681-3689.
175. La Rosa C., Longmate J., Lacey S.F., Kaltcheva T., Sharan R., Marsano D., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205(April (8)):1294-1304.
176. Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987, 317(October (17)):1049-1054.
177. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26(October (45)):5760-5766.
178. Genini E., Percivalle E., Sarasini A., Revello M.G., Baldanti F., Gerna G. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011, 52(October (2)):113-118.
179. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 2008, 89(April (Pt 4)):853-865.
180. Cui X., Adler S.P., Davison A.J., Smith L., Habib el S.E., McVoy M.A. Bacterial artificial chromosome clones of viruses comprising the Towne cytomegalovirus vaccine. J Biomed Biotechnol 2012, 2012. 428498. 10.1155/2012/428498.
181. Patrone M., Secchi M., Fiorina L., Ierardi M., Milanesi G., Gallina A. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 2005, 79(July (13)):8361-8373.
182. Quinnan G.V., Delery M., Rook A.H., Frederick W.R., Epstein J.S., Manischewitz J.F., et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 1984, 101(October (4)):478-483.
183. Plotkin S.A., Huang E.S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985, 152(August (2)):395-397.
184. Oxford K.L., Strelow L., Yue Y., Chang W.L., Schmidt K.A., Diamond D.J., et al. Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys. J Virol 2011, 85(May (10)):5105-5114.
185. Morello C.S., Ye M., Hung S., Kelley L.A., Spector D.H. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 2005, 79(January (1)):159-175.
186. Abel K., Strelow L., Yue Y., Eberhardt M.K., Schmidt K.A., Barry P.A. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine 2008, 26(November (47)):6013-6025.
187. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003, 77(May (9)):5226-5240.
188. Abel K., Martinez J., Yue Y., Lacey S.F., Wang Z., Strelow L., et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 2011, 85(March (6)):2878-2890.
189. Morello C.S., Kelley L.A., Munks M.W., Hill A.B., Spector D.H. DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol 2007, 81(July (14)):7766-7775.
190. Schleiss M.R. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol 2008, 325:361-382.